Air Pollution Linked to Worse Outcomes for COVID-19 Patients
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, June 26, 2023 -- For patients with COVID-19, exposure to air pollution is associated with increased duration of hospitalization and with increased risk of adverse outcomes, according to two studies published online June 21 in the European Respiratory Journal.
Stijn Vos, from Hasselt University in Belgium, and colleagues recruited 328 hospitalized COVID-19 patients from two hospitals and modeled daily exposure levels for particulate matter (PM2.5 and PM10), nitrogen dioxide (NO2), and black carbon using a high-resolution spatiotemporal model. The researchers found that an interquartile range increase in exposure in the week before admission was associated with increased duration of hospitalization (PM2.5: +4.22 days; NO2: +4.33 days). Similar effects on hospitalization duration were seen for long-term NO2 and black carbon exposure.
Jiawei Zhang, from the University of Copenhagen in Denmark, and colleagues followed 3,721,810 Danish residents 30 years and older in the National COVID-19 Surveillance System. The associations of air pollutants with COVID-19 outcomes were estimated. The researchers found that during 14 months, 138,742 individuals were infected, 11,270 were hospitalized, and 2,557 died from COVID-19. PM2.5 (per 0.5 µg/m-3) and NO2 (per 3.6 µg/m-3) were associated with COVID-19 incidence (hazard ratios, 1.10 and 1.18, respectively), hospitalizations (hazard ratios, 1.09 and 1.19, respectively), and death (hazard ratios, 1.23 and 1.18, respectively). The associations were strongest in the lowest socioeconomic groups and for those with chronic respiratory, cardiometabolic, and neurodegenerative disease.
"This article reinforces the evidence that community intervention on air pollution abatement would be a very effective way to protect our population from the impact of COVID-19, with the co-benefit of the protection against other respiratory infections as well," write the authors of an accompanying editorial.
Several authors from the second study reported ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Further Support and Information on COVID-19
Read this next
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
Race-Neutral Metrics More Accurately Predict Risk in COPD
FRIDAY, May 31, 2024 -- Race-neutral metrics more accurately predict the risk for death and exacerbations in chronic obstructive pulmonary disease (COPD), according to a study...
Mortality Higher for COVID-19 Hospitalization Than for Flu in 2023/2024 Season
WEDNESDAY, May 22, 2024 -- In fall/winter 2023/2024, the risk for death in patients hospitalized for COVID-19 was greater than the risk for death in patients hospitalized for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.